Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Our approach
Proprietary Technology
NeoVAC, our main product in development, which is aimed to enter the clinic in 2020, is developed utilizing our proprietary PersoVAC™, AmpliVax™, PyroVant™ and CADVax™ technologies.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide/RNA vaccines, or cell-based immunotherapies.
Company Highlights
About Us
Company Background
Immunetune, based in Leiden, the Netherlands, is a dedicated and fast-moving biotech company committed to develop personalized, tumor-specific vaccines to fight cancer and prevent its recurrence.
News
Important Regulatory Milestone achieved for Immunetune’s NeoVAC platform
Immunetune is proud to announce that they can continue their regulatory pathway, following supportive Scientific Advice from the Paul-Ehrlich Institute (PEI) in Germany on the 18th of June 2020.
Biotechgate Digital Partnering 31 Aug – 3 Sep 2020
Roger Legtenberg, CBO of Immunetune, will attend the Biotechgate Digital Partnering event on 31 Aug - 3 Sep, 2020. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.
Immunetune joins the fight against Sars-CoV-2
Within a newly established consortium, Immunetune will develop enhanced DNA vaccines against SARS-CoV-2 and other human coronaviruses. The vaccine is built on the combination of two strong synthetic vaccine platforms and the inclusion of conserved T and B cell...